• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetics of amikacin in hematologic malignancies.阿米卡星在血液系统恶性肿瘤中的药代动力学。
Antimicrob Agents Chemother. 1989 Aug;33(8):1406-8. doi: 10.1128/AAC.33.8.1406.
2
Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey.恒河猴单次或重复静脉注射后，低清除率单层脂质体中阿米卡星的药代动力学和尿排泄情况。
Antimicrob Agents Chemother. 1999 Mar;43(3):503-9. doi: 10.1128/AAC.43.3.503.
3
Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis.接受缓慢血液透析的危重症患者单剂量静脉注射阿米卡星的药代动力学
Intensive Care Med. 1995 Apr;21(4):348-51. doi: 10.1007/BF01705414.
4
Pharmacokinetics and intramuscular bioavailability of amikacin in chickens following single and multiple dosing.单次和多次给药后鸡体内阿米卡星的药代动力学和肌肉注射生物利用度
J Vet Pharmacol Ther. 1992 Jun;15(2):133-42. doi: 10.1111/j.1365-2885.1992.tb01000.x.
5
Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy.接受大剂量癌症化疗患者的阿米卡星药代动力学
Antimicrob Agents Chemother. 1991 May;35(5):944-7. doi: 10.1128/AAC.35.5.944.
6
Pharmacokinetics of amikacin in lactating goats.阿米卡星在泌乳山羊体内的药代动力学
Zentralbl Veterinarmed A. 1999 May;46(4):239-46. doi: 10.1046/j.1439-0442.1999.00212.x.
7
Pharmacokinetics of amikacin in neonates.阿米卡星在新生儿中的药代动力学。
Dev Pharmacol Ther. 1993;20(3-4):167-73. doi: 10.1159/000457558.
8
Population pharmacokinetic study of teicoplanin in severely neutropenic patients.替考拉宁在严重中性粒细胞减少患者中的群体药代动力学研究。
Antimicrob Agents Chemother. 1996 May;40(5):1242-7. doi: 10.1128/AAC.40.5.1242.
9
Pharmacokinetics of amikacin during continuous veno-venous hemofiltration.阿米卡星在持续静脉-静脉血液滤过过程中的药代动力学。
Crit Care Med. 1990 Jun;18(6):675-6. doi: 10.1097/00003246-199006000-00023.
10
Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients.囊性纤维化患者每日单次剂量阿米卡星的药代动力学和支气管扩散
J Antimicrob Chemother. 1997 Mar;39(3):431-3. doi: 10.1093/jac/39.3.431.

引用本文的文献

1
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.重症患者的抗菌治疗：对导致药物处置改变和药代动力学变异性的病理生理状况的综述。
Clin Pharmacokinet. 2005;44(10):1009-34. doi: 10.2165/00003088-200544100-00002.
2
Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.替考拉宁用于急性白血病合并发热性中性粒细胞减少症患者：受益于更高剂量的特殊人群。
Clin Pharmacokinet. 2004;43(6):405-15. doi: 10.2165/00003088-200443060-00004.
3
Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina.
Eur J Drug Metab Pharmacokinet. 2003 Jan-Mar;28(1):1-6. doi: 10.1007/BF03190860.
4
Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients.奈替米星在香港中国癌症患者中的药代动力学。
Br J Clin Pharmacol. 1999 Jul;48(1):33-5. doi: 10.1046/j.1365-2125.1999.00955.x.
5
Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.对发热、严重中性粒细胞减少的成年人每日给药一次或两次的阿米卡星群体药代动力学研究。
Antimicrob Agents Chemother. 1998 Apr;42(4):849-56. doi: 10.1128/AAC.42.4.849.
6
Once daily antibiotic regimen in paediatric oncology.儿科肿瘤学中的每日一次抗生素治疗方案。
Arch Dis Child. 1994 Jun;70(6):484-7. doi: 10.1136/adc.70.6.484.
7
Gentamicin volume of distribution in critically ill septic patients.庆大霉素在重症脓毒症患者中的分布容积。
Intensive Care Med. 1990;16(5):303-6. doi: 10.1007/BF01706354.
8
Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy.接受大剂量癌症化疗患者的阿米卡星药代动力学
Antimicrob Agents Chemother. 1991 May;35(5):944-7. doi: 10.1128/AAC.35.5.944.

本文引用的文献

1
The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.氨基糖苷类血浆水平与革兰氏阴性菌血症患者死亡率的关联。
J Infect Dis. 1984 Mar;149(3):443-8. doi: 10.1093/infdis/149.3.443.
2
Comparative pharmacokinetics of amikacin and kanamycin.阿米卡星和卡那霉素的比较药代动力学
Clin Pharmacol Ther. 1974 Jun;15(6):610-6. doi: 10.1002/cpt1974156610.
3
Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis.严重革兰氏阴性菌败血症治疗期间监测庆大霉素治疗的经验。
Br Med J. 1974 Mar 16;1(5906):477-81. doi: 10.1136/bmj.1.5906.477.
4
Aminoglycoside volume of distribution in hematology-oncology patients.
Clin Pharm. 1986 Aug;5(8):629, 632.
5
Prediction of creatinine clearance from serum creatinine.根据血清肌酐预测肌酐清除率。
Nephron. 1976;16(1):31-41. doi: 10.1159/000180580.
6
Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function.阿米卡星治疗肾功能减退患者尿路感染的药代动力学
J Infect Dis. 1976 Nov;134 SUPPL:S369-73. doi: 10.1093/infdis/135.supplement_2.s369.
7
Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay.阿米卡星在肾功能正常或受损患者中的药代动力学：放射酶法乙酰化测定
J Infect Dis. 1976 Nov;134 SUPPL:S323-30. doi: 10.1093/infdis/135.supplement_2.s323.
8
Clinical pharmacology of amikacin and kanamycin.阿米卡星和卡那霉素的临床药理学
J Infect Dis. 1976 Nov;134 SUPPL:S312-5. doi: 10.1093/infdis/135.supplement_2.s312.
9
The pharmacokinetics of amikacin in children.阿米卡星在儿童中的药代动力学。
J Pediatr. 1977 Aug;91(2):333-9. doi: 10.1016/s0022-3476(77)80847-0.
10
Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic.新型氨基糖苷类抗生素阿米卡星的药代动力学及临床研究。
J Infect Dis. 1976 Nov;134 SUPPL:S316-22. doi: 10.1093/infdis/135.supplement_2.s316.

阿米卡星在血液系统恶性肿瘤中的药代动力学。

Pharmacokinetics of amikacin in hematologic malignancies.

作者信息

Kaojarern S, Maoleekoonpairoj S, Atichartakarn V

机构信息

Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand.

出版信息

Antimicrob Agents Chemother. 1989 Aug;33(8):1406-8. doi: 10.1128/AAC.33.8.1406.

DOI:10.1128/AAC.33.8.1406
PMID:2802567
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC172668/
Abstract

The pharmacokinetics of amikacin in 10 patients with hematologic malignancies and 1 patient with aplastic anemia were investigated. At an administered dose of 7 mg/kg of body weight, a volume of distribution of 0.4 liters/kg, an elimination half-life of 3.0 h, and a total body clearance of 2.1 ml/min per kg, amikacin achieved a peak level in blood of 21 micrograms/ml. Results of the study revealed that there was a marked increase in volume of distribution of amikacin in these patients compared with normal.

摘要

对10例血液系统恶性肿瘤患者和1例再生障碍性贫血患者的阿米卡星药代动力学进行了研究。给予7mg/kg体重的剂量时，分布容积为0.4升/千克，消除半衰期为3.0小时，全身清除率为2.1毫升/分钟/千克，阿米卡星在血液中的峰值水平达到21微克/毫升。研究结果显示，与正常人相比，这些患者体内阿米卡星的分布容积显著增加。